KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cost of Revenue (2017 - 2025)

Historic Cost of Revenue for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $510.5 million.

  • Amneal Pharmaceuticals' Cost of Revenue rose 1793.19% to $510.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 709.39%. This contributed to the annual value of $1.8 billion for FY2024, which is 1274.45% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Cost of Revenue is $510.5 million, which was up 1793.19% from $438.3 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Cost of Revenue's 5-year high stood at $510.5 million during Q3 2025, with a 5-year trough of $301.5 million in Q1 2021.
  • Its 5-year average for Cost of Revenue is $394.1 million, with a median of $387.5 million in 2023.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Cost of Revenue crashed by 677.84% in 2021 and then surged by 1920.93% in 2024.
  • Amneal Pharmaceuticals' Cost of Revenue (Quarter) stood at $371.2 million in 2021, then increased by 6.25% to $394.4 million in 2022, then rose by 8.31% to $427.2 million in 2023, then increased by 9.48% to $467.6 million in 2024, then grew by 9.17% to $510.5 million in 2025.
  • Its Cost of Revenue stands at $510.5 million for Q3 2025, versus $438.3 million for Q2 2025 and $439.5 million for Q1 2025.